Simplifying Global Compliance
FDAnews Drug Daily Bulletin
FDA Accepts Exelixis Treatment for Priority Review
Aug. 1, 2012
Drugmaker Exelixis said the Food and Drug Administration has accepted its potential thyroid cancer treatment, carbozantinib, for priority review.
San Francisco Chronicle
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing